Kyowa Hakko in-licenses ARQ 197, an anticancer agent in clinical development, from the US company ArQule.
- Category: Small Molecules
- Published on Saturday, 28 April 2007 04:00
- Hits: 1810
WOBURN, MA, USA | Apr 27, 2007 | Kyowa Hakko Kogyo Co., Ltd. based in Tokyo, Japan (President and CEO: Dr. Yuzuru Matsuda) entered into a license agreement with the US drug development company ArQule based in Massachusetts, US (President and CEO: Dr. Stephen A. Hill), whereby Kyowa Hakko will be granted the exclusive right to develop and market the anticancer agent ARQ 197 for the treatment of solid tumors in Japan and some other Asian regions (China, South Korea, and Taiwan). Having completed phase I studies in the US, ArQule is now making preparations for starting the next phase of clinical development of ARQ 197.
Under this agreement, Kyowa Hakko will carry out the clinical program of ARQ 197 for its registration and commercialization in Japan. ArQule will receive from Kyowa Hakko an upfront payment of 30 million dollars, milestone payments and royalties at various stages of development and product sales.
ARQ 197 is a molecularly targeted compound that exerts anticancer activity by inhibiting a receptor tyrosine kinase known as c-Met. This small molecule anticancer agent can be administered orally.
c-Met, which acts as a receptor for hepatocyte growth factor (HGF) / scatter factor (SF), is known to regulate a variety of physiological processes such as cell proliferation and survival. It has been shown that c-Met is activated in many types of malignancies, particularly in gastrointestinal cancers including stomach cancer, and plays roles in the aberrant growth, metastasis and other characteristics of cancer cells.
ARQ 197 selectively inhibits c-Met, thereby blocking these features specific to cancer cells which leads to the anticancer activities.
The phase I studies conducted in the US have demonstrated that ARQ 197 is safe with no serious side effects, and shows signs of anti-tumor activity in cancer patients with different types of solid tumors. These encouraging results warrant further clinical investigation of ARQ 197, which has the potential to provide therapeutic benefit as a novel anticancer drug with a favorable safety profile.
Kyowa Hakko is making an extensive contribution to the treatment of cancer through the marketing of a number of anticancer drugs: Mitomycin, 5-FU, Navelbine(R), Adriacin(R), Farmorubicin(R), Leunase(R), Hysron(R)-H, Dacarbazine, and Platosin(R). Its commitment to this field is also demonstrated in several products used to support cancer management: Neu-up(R), Leukoprol(R), Navoban(R), and Durotep(R), a narcotic skin patch for the relief of cancer pain.
In R&D, oncology is one of Kyowa HakkoAfs focus areas. Its ongoing clinical projects include some anticancer drug candidates, such as KW-2449, an internally developed kinase inhibitor targeting a molecule other than c-Met, and therapeutic antibodies, as well as an analgesic for cancer pain. The in-licensing of ARQ 197 will help us contribute further to the oncology area.
SOURCE: Kyowa Hakko Kogyo Co., Ltd